Compare Abeona Therapeutics Inc (ABEO) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs DENTSPLY SIRONA Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while DENTSPLY SIRONA Inc trades at $11.77 (market cap $2.44B). The key difference: DENTSPLY SIRONA Inc is far larger — about 6.5× Abeona Therapeutics Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | XRAY | |
|---|---|---|
Market Cap | $373.32M | $2.44B |
Sector | Health | Health |
52-Week High | $7.23 | $16.85 |
52-Week Low | $4.17 | $9.64 |
Enterprise Value | $228.22M | $4.58B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
XRAY trades at $12.19, up 4.64% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q1 2026 EPS of $0.27, missing estimates of $0.28, continuing a trend of earnings misses. Revenue declined to $3.68B in 2025 with a net loss of $598M, though gross margin remains healthy at 48.93%. Recent news highlights distribution expansions and AI-enabled product launches, supporting growth initiatives amid ongoing profitability challenges.
The outlook remains mixed: analyst consensus is a 'Hold' with a $12.50 price target, near current levels. Upside potential exists from digital dentistry adoption and cost controls, but risks include persistent net losses, high debt-to-asset ratio of 42.88%, and competitive pressures. Investors should weigh stabilization efforts against margin headwinds and macroeconomic softness in European markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
